10 Years of T Cell Research in Rheumatoid Arthritis Mapped in 7,037 Papers

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 0.5% of the global population, characterized by synovial inflammation, joint destruction, and significant disability. T cells are central to RA pathogenesis, orchestrating adaptive immune responses that drive autoantibody production, synovitis, and bone erosion. Despite extensive individual studies, no comprehensive bibliometric synthesis of T cell research in RA had previously been conducted — a gap this study aimed to fill by mapping a decade of scientific output.

The authors searched the Web of Science Core Collection using a broad T cell terminology strategy combined with 'rheumatoid arthritis,' covering 2014 to 2023. After excluding non-English documents and non-standard document types (meeting abstracts, editorials, letters, book chapters, etc.), 7,037 articles and reviews were retained for analysis. Of these, 4,792 (63.25%) were original articles and 2,368 (31.26%) were reviews. CiteSpace 6.2.R6 and VOSviewer 1.6.19 were used for network visualization, while Scimago Graphica provided geographic distribution mapping and Microsoft Excel tracked publication trends over time.

Publications originated from 100 countries and regions, with the USA (25.35%, n=1,784) and China (25.02%, n=1,761) dominating output. The UK (9.35%), Japan (7.69%), and Germany (7.05%) rounded out the top five. Notably, China overtook the USA in annual publications after 2020, reflecting rapid growth in Chinese research infrastructure. Citation impact was highest for the USA (average 44.06 citations per item), UK (43.87), and Germany (40.49), suggesting that while China leads in volume, Western institutions still produce more highly cited work. Karolinska Institute (138 papers) and Harvard Medical School (128 papers) were the top institutional contributors. The most prolific authors were Wei W, Cho ML, and Park SH, while McInnes IB and Smolen JS were the most frequently cited, reflecting their foundational contributions to RA immunology.

Keyword co-occurrence and burst analysis identified four major current research hotspots: (1) pathogenic factors and targeted biologic therapy, including JAK inhibitors and TNF blockers; (2) immune mechanisms, particularly Th17/Treg imbalance and regulatory T cell dysfunction; (3) inflammatory mechanisms involving cytokine networks such as IL-6, IL-17, and TNF-α; and (4) bone destruction mechanisms mediated by osteoclast activation. Emerging research frontiers — identified through citation burst analysis as topics gaining rapid recent attention — include gut microbiota and its influence on immune dysregulation, fibroblast-like synoviocytes (FLS) as active participants in joint destruction, mesenchymal stem cell (MSC) therapy, refined biologic treatment strategies, and risk factor identification for disease onset and progression.

The dual-map overlay of journals revealed that T cell–RA research spans molecular/immunological science and clinical medicine, with Frontiers in Immunology, Arthritis Research & Therapy, and Arthritis & Rheumatology publishing the most papers in this space. The analysis highlights that while the field has matured in understanding classical T cell subsets (Th1, Th17, Treg), newer directions — particularly the microbiome–immune axis and stromal cell interactions — represent the next wave of mechanistic and therapeutic investigation. For clinicians, the convergence of biologic therapy refinement and emerging MSC-based approaches signals a broadening therapeutic landscape for RA patients who fail conventional DMARDs.